Clinical Trial Update: Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric [Phase 3]

View source ↗

Summary

Phase 3 trial investigating inhaled nitric oxide in PAH patients with LTOT use was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Snippet

Sponsor: Bellerophon Pulse Technologies | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: WITHDRAWN